MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.190
+0.130
+6.31%
Closed 16:00 05/14 EDT
OPEN
2.060
PREV CLOSE
2.060
HIGH
2.240
LOW
2.060
VOLUME
198.84K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
1.740
MARKET CAP
119.21M
P/E (TTM)
-2.2494
1D
5D
1M
3M
1Y
5Y
Robert W. Baird Maintains Their Buy Rating on Genocea Biosciences (GNCA)
In a report issued on April 29, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Genocea Biosciences (GNCA), with a price target of $8.00.
SmarterAnalyst · 05/03 07:11
Genocea Biosciences Files $300 Million Mixed Shelf
MT Newswires · 04/30 03:12
Genocea Biosciences (GNCA) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (GNCA) today and set a price target of $9.00. The company's shares
SmarterAnalyst · 04/29 16:15
Genocea Biosciences (GNCA) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 04/29 12:55
8-K: GENOCEA BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- 0001457612false00014576122021-04-292021-04-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/29 12:36
BRIEF-Genocea Biosciences Inc - Qtrly Loss Per Share of $0.17
reuters.com · 04/29 11:43
Genocea Biosciences EPS beats by $0.03
Genocea Biosciences (GNCA): Q1 GAAP EPS of -$0.17 beats by $0.03.Cash position: As of March 31, 2021, cash and cash equivalents were $66.0 million compared to $79.8 million as of
Seekingalpha · 04/29 11:18
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Apr 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a...
GlobeNewswire · 04/22 20:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNCA stock price target is 6.68 with a high estimate of 9.00 and a low estimate of 4.400.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 32.61M
% Owned: 59.90%
Shares Outstanding: 54.43M
TypeInstitutionsShares
Increased
13
2.54M
New
9
2.52M
Decreased
4
16.62K
Sold Out
9
1.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Senior Vice President
Narinderjeet Singh
Chief Scientific Officer
Jessica Flechtner
Senior Vice President
Narinder Singh
Other
Girish Aakalu
Other
Thomas Davis
Director
Gisela Schwab
Independent Director
Ali Behbahani
Independent Director
Katrine Bosley
Independent Director
Michael Higgins
Independent Director
George Siber
No Data
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.